Availability of Q1 2022 memorandum for modeling purposes

0

Sanofi-Aventis Group

Availability of Q1 2022 memorandum for modeling purposes

Paris, March 30, 2022. Sanofi today announces that its Q1 2022 Memorandum for modeling purposes is available on the “Investors” page of the company’s website:

https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q1-results-2022

As for each quarter, Sanofi has prepared this document to assist in the financial modeling of the Group’s quarterly results. This document includes a reminder of various non-comparable items and losses of exclusivity as well as the impact of currencies and the number of shares. Sanofi’s first quarter 2022 results will be released on April 28, 2022.

On Sanofi
We are an innovative global healthcare company driven by one purpose: we pursue the miracles of science to improve people’s lives. Our team, present in over 100 countries, is dedicated to transforming the practice of medicine by striving to turn the impossible into the possible. We provide potentially game-changing treatment options and life-saving vaccine protection to millions of people around the world, while placing sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | [email protected]
Sally Bath | + 1 617 834 6026 | [email protected]
Victor Rouault | + 33 6 70 93 71 40 | [email protected]

Investor Relations
Eva Schäfer-Jansen | + 33 7 86 80 56 39 | [email protected]
Arnaud Delepine | + 33 6 73 69 36 93 | [email protected]
Corentine Driancourt | + 33 6 40 56 92 21 | [email protected]
Felix Lauscher | + 1 908 612 7239 | [email protected]
Priya Nanduri | +1 908 981 5560 | [email protected]
Nathalie Pham | + 33 7 85 93 30 17 | [email protected]

Sanofi forward-looking statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations regarding future financial results, events, operations, services, development and potential of products, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in these forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Sanofi’s control. , which could cause actual results and developments to differ materially from those expressed, implied or projected by the forward-looking information and statements. These risks and uncertainties include, among others, uncertainties inherent in research and development, future clinical data and analyses, including post-marketing, decisions of regulatory authorities, such as the FDA or EMA, regarding the whether and when to approve any drug, device or biologic that may be filed for these product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of these product candidates, the fact that the product candidates, if approved, may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to enter into related transactions and/or obtain regulatory approvals, intellectual property risks and any pending litigation or future partner and the ultimate outcome of such litigation, prevailing currency and interest rate trends, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors and other business partners, and the financial condition of any of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the above may also adversely impact us. This situation is changing rapidly and additional impacts may arise that we are not currently aware of and may exacerbate other previously identified risks. Risks and uncertainties also include uncertainties discussed or identified in public filings with the SEC and AMF by Sanofi, including those listed under “Risk Factors” and “Caution Regarding Forward-Looking Statements” in the Sanofi’s Annual Report on Form 20-F for the fiscal year ended December 31, 2021. Except as required by applicable law, Sanofi undertakes no obligation to update or revise any forward-looking information or statements.

Attachment

Share.

Comments are closed.